Helix Bridge Advisors | Ex: CSL Behring
Kapil K. is a senior biopharmaceutical CMC, Technical Operations, Process Development, MSAT, and manufacturing leader with more than 22 years of experience spanning commercial biologics, recombinant proteins, monoclonal antibodies, vaccines, plasma-derived therapies, sterile drug products, and AAV gene therapy. Most recently, he served as Director of Process Engineering and MSAT at CSL Behring, where he provided global technical and lifecycle leadership for commercial and late-stage biopharmaceutical products, including AAV gene therapy, recombinant coagulation factors, and plasma-derived products. Kapil has extensive experience across the complete product lifecycle, from early process development and scale-up through technology transfer, process characterization, PPQ, regulatory submission, commercial launch, continued process verification, post-approval changes, deviation investigations, and lifecycle optimization. His expertise covers both drug substance and drug product manufacturing, including upstream processing, downstream purification, aseptic processing, formulation, fill-finish, packaging interfaces, cold-chain operations, and commercial supply support. His upstream expertise includes mammalian cell culture, microbial fermentation, yeast expression, HEK293 and insect-cell-based AAV production, baculovirus systems, seed-train design, media development and optimization, raw material qualification, feeding strategies, bioreactor scale-up, process intensification, single-use bioreactors, disposable mixing systems, and large-scale stainless-steel and single-use manufacturing platforms. He has supported processes ranging from laboratory and pilot scale through 2,000-liter commercial manufacturing. Kapil also has deep downstream-processing expertise, including centrifugation, depth filtration, tangential-flow filtration, ultrafiltration and diafiltration, clarification, viral clearance, affinity chromatography, ion-exchange chromatography, hydrophobic-interaction chromatography, multimodal chromatography, membrane chromatography, AAV full-versus-empty capsid enrichment, formulation, bulk drug substance handling, and sterile filtration. He has evaluated and implemented chromatography resins, filtration technologies, single-use flow paths, process skids, and manufacturing equipment across clinical and commercial operations. His drug product experience includes formulation development support, aseptic filling, vial and prefilled-syringe operations, isolator and restricted-access-barrier-system technologies, equipment qualification, media fills, aseptic process simulations, container-closure integrity, visual inspection, extractables and leachables, frozen and refrigerated product configurations, shipping validation, cold-chain distribution, and drug product PPQ readiness. At CSL Behring, Kapil provided technical leadership for the commercial AAV gene therapy HEMGENIX and supported process robustness, potency improvement, upstream baculovirus and cell-culture performance, downstream purification, full-and-empty capsid control, process characterization, manufacturing investigations, validation strategy, regulatory commitments, and external manufacturing governance. He also supported recombinant and plasma-derived products, manufacturing network transfers, product stewardship, process monitoring, and global health-authority interactions. Prior to CSL Behring, Kapil worked at Merck & Co. in biologics process development, commercialization, and manufacturing support. His work included upstream process development and commercial readiness for monoclonal antibodies, including KEYTRUDA, technology transfers to external manufacturing partners, process characterization, scale-up, manufacturing investigations, validation strategy, and late-stage CMC support. He also supported vaccine manufacturing and commercial MSAT activities. At Teva Pharmaceutical Industries, Kapil served in Global CMC Biologics and supported late-stage development, process characterization, validation readiness, regulatory filing preparation, commercial manufacturing strategy, facility design, and technology transfer for biologics. His work included monoclonal antibodies, recombinant proteins, yeast-based processes, drug substance manufacturing, drug product operations, and the design and implementation of large-scale single-use manufacturing facilities. Kapil spent approximately eight years at Genentech, where he held increasingly responsible positions in process development and engineering. He developed and scaled mammalian cell-culture and purification processes for monoclonal antibodies, recombinant proteins, antibody-drug conjugates, and other biologics. His responsibilities included laboratory and pilot-plant operations, upstream and downstream process development, scale-up, technology transfer, process modeling, equipment design, process characterization, clinical manufacturing support, IND-enabling activities, CMC documentation, and commercial product support. His experience included products and platforms associated with major biologics franchises such as Avastin and Lucentis. Earlier in his career, Kapil worked in cell-culture process development at GlaxoSmithKline and in bioprocess equipment and technology applications at Millipore. These roles provided him with foundational expertise in fermentation, mammalian cell culture, bioreactor engineering, filtration, chromatography, disposable processing systems, equipment selection, process scale-up, and biomanufacturing facility operations. Kapil has led and supported global cross-functional teams involving Process Development, Manufacturing, MSAT, Quality, Regulatory CMC, Analytical Development, Engineering, Validation, Supply Chain, Procurement, Finance, and external manufacturing partners. He has managed technical programs, budgets, timelines, vendor relationships, statements of work, technical due diligence, contract negotiations, capital projects, manufacturing readiness activities, and senior-management governance. He has extensive experience working with contract development and manufacturing organizations and external partners, including technical evaluation, vendor selection, capability assessments, due diligence, technology transfer, engineering runs, process validation, commercial manufacturing oversight, quality and technical governance, investigation support, performance management, and remediation planning. His external-manufacturing experience spans biologics, gene therapy, plasma-derived products, recombinant proteins, and sterile drug products. Kapil is experienced in applying Quality by Design, risk-based process development, design of experiments, process analytical technology, statistical process control, multivariate data analysis, failure mode and effects analysis, root-cause analysis, process capability assessment, continued process verification, and manufacturing data trending. He has used tools such as JMP, Power BI, Tableau, and other digital manufacturing and data-visualization platforms to assess process performance, identify sources of variability, and support technical decision-making. His regulatory and compliance experience includes current Good Manufacturing Practices, FDA and EMA expectations, ICH guidelines, process validation, equipment qualification, cleaning validation, aseptic processing, data integrity, change control, deviation management, CAPA, comparability, inspection readiness, regulatory CMC submissions, health-authority responses, post-approval commitments, and global lifecycle management. Kapil is available to consult on topics including: • Biologics and gene-therapy process development • AAV manufacturing and HEK293 or insect-cell production platforms • Baculovirus expression vector systems • Mammalian cell culture and microbial fermentation • Upstream and downstream bioprocessing • Cell-line and expression-system selection • Media, feeds, supplements, and raw-material strategies • Single-use versus stainless-steel manufacturing technologies • Bioreactor, mixing, filtration, and chromatography technologies • AAV purification and full-versus-empty capsid enrichment • Drug substance and drug product manufacturing • Aseptic processing and sterile fill-finish • Process scale-up, scale-down models, and process characterization • Technology transfer and manufacturing-site readiness • PPQ, process validation, and continued process verification • CMC strategy from clinical development through commercialization • Commercial product stewardship and lifecycle management • Manufacturing investigations, root-cause analysis, and CAPA • Process robustness, yield, potency, quality, and cost improvement • External manufacturing, CDMO selection, and supplier governance • Biomanufacturing facility design and capacity planning • Single-use equipment, consumables, filters, resins, and supply chains • Raw-material and media supplier evaluation • Manufacturing digitalization, process monitoring, and data analytics • Regulatory submissions, health-authority interactions, and inspection readiness • Validation, qualification, CSV, data integrity, and quality systems • Vendor selection, statements of work, technical contracts, and outsourcing strategy • Artificial intelligence and advanced analytics in process development, manufacturing, validation, and quality workflows • Technical due diligence, acquisitions, partnerships, and manufacturing-network strategy • Organization design, team development, operational excellence, and technical leadership Kapil holds a Bachelor of Science degree in Chemical Engineering from the University of Mumbai and a Master of Science degree in Chemical Engineering and Biotechnology from the University of Massachusetts Lowell. Biopharmaceutical Manufacturing; Biologics CMC; Chemistry, Manufacturing and Controls; Technical Operations; Manufacturing Science and Technology; MSAT; Process Development; Process Engineering; Drug Substance; Drug Product; AAV Gene Therapy; Viral Vector Manufacturing; HEK293; Insect Cell Culture; Sf9 Cell Culture; Baculovirus Expression Vector System; Monoclonal Antibodies; Recombinant Proteins; Plasma-Derived Products; Coagulation Factors; Vaccines; Antibody-Drug Conjugates; Mammalian Cell Culture; Microbial Fermentation; Yeast Fermentation; Cell-Line Development; Media Development; Media Optimization; Raw Materials; Bioreactors; Seed Train; Scale-Up; Scale-Down Models; Process Intensification; Single-Use Technology; Disposable Bioreactors; Stainless-Steel Manufacturing; Upstream Processing; Downstream Processing; Harvest; Clarification; Centrifugation; Depth Filtration; Tangential-Flow Filtration; Ultrafiltration; Diafiltration; Sterile Filtration; Chromatography; Affinity Chromatography; Ion-Exchange Chromatography; Membrane Chromatography; Hydrophobic-Interaction Chromatography; Multimodal Chromatography; Viral Clearance; AAV Purification; Full and Empty Capsids; Formulation; Aseptic Processing; Sterile Fill-Finish; Vial Filling; Prefilled Syringes; Isolators; RABS; Media Fills; Container-Closure Integrity; Extractables and Leachables; Cold Chain; Frozen Drug Product; Technology Transfer; Process Characterization; PPQ; Process Validation; Equipment Qualification; Cleaning Validation; Continued Process Verification; Commercial Manufacturing; Product Lifecycle Management; Product Stewardship; Manufacturing Investigations; Deviations; CAPA; Root-Cause Analysis; FMEA; Quality by Design; Design of Experiments; Statistical Process Control; Multivariate Data Analysis; JMP; Power BI; Process Analytical Technology; Digital MSAT; cGMP; FDA; EMA; ICH; Regulatory CMC; Module 3; Comparability; Post-Approval Changes; Inspection Readiness; External Manufacturing; CDMO Management; CMO Management; Supplier Qualification; Vendor Selection; Technical Due Diligence; Contract Negotiation; Statements of Work; Capital Projects; Facility Design; Capacity Planning; Operational Excellence; Cost of Goods; Yield Improvement; Potency Improvement; Process Robustness; Supply Risk Management; Validation Services; CSV; Data Integrity; Artificial Intelligence in Manufacturing; AI in Quality; AI in Validation; Cross-Functional Leadership; Global Team Leadership; Technical Leadership; People Management; Portfolio Management; Program Management; Manufacturing Strategy.
Helix Bridge Advisors
Consultant for Bioprocess Development , CMC , Upstream, Downstream Unit Operations, Technology Transfers
CSL Behring
Provided global CMC, Process Engineering, MSAT, Technical Operations, and lifecycle leadership for commercial AAV gene therapy, recombinant biologics, coagulation factors, and plasma-derived products. Served as a technical leader for HEMGENIX, supporting Sf9 cell culture, baculovirus expansion, MOI strategy, media and raw-material controls, single-use bioreactors, harvest, purification, formulation, potency, and process robustness. Led upstream and downstream investigations involving cell growth, baculovirus performance, potency variability, yield, full and empty capsids, chromatography, filtration, microbial control, equipment performance, and assay variability. Supported drug-substance and drug-product process characterization, scale-down models, PPQ, process validation, continued process verification, comparability, change control, CAPA, and post-approval lifecycle management. Provided expertise in affinity chromatography, ion-exchange chromatography, membrane chromatography, TFF, UF/DF, depth filtration, sterile filtration, frozen storage, aseptic processing, and drug-product configuration. Managed external manufacturing and CDMO activities, including technology transfer, manufacturing readiness, vendor assessment, SOW development, technical governance, performance oversight, and issue escalation. Supported regulatory CMC submissions, briefing packages, health-authority responses, inspection readiness, regulatory commitments, and global change strategies. Applied DOE, FMEA, RCA, JMP, multivariate analysis, process monitoring, Power BI, data trending, and risk-based decision-making to improve process performance and supply reliability.
Merck
Led upstream process development, commercialization, technology transfer, and manufacturing support for monoclonal antibodies, vaccines, and recombinant biologics. Supported late-stage and commercial programs, including KEYTRUDA and other antibody products, across internal and external manufacturing networks. Provided expertise in mammalian cell culture, seed trains, media and feeds, bioreactor scale-up, process characterization, process intensification, scale-down models, and commercial process definition. Supported engineering runs, PPQ readiness, process validation, control strategy, critical process parameter assessment, continued process verification, and manufacturing performance monitoring. Led process troubleshooting, deviation investigations, root-cause analysis, CAPA, comparability assessments, change controls, and process robustness improvements. Evaluated single-use and stainless-steel equipment, media preparation, mixing, mass transfer, raw materials, process hold times, sampling strategy, and facility fit. Supported technology transfers to external manufacturing partners, including process fit, technical risk assessment, manufacturing readiness, and execution governance. Contributed to regulatory CMC documentation, health-authority responses, cross-functional technical reviews, and commercialization decisions.
Teva Pharmaceuticals
Supported global CMC, process development, scale-up, validation, technology transfer, and commercialization for monoclonal antibodies, recombinant proteins, and sterile biologic products. Worked on late-stage programs, including AJOVY, supporting Phase III readiness, process characterization, BLA preparation, PPQ strategy, and commercial manufacturing planning. Provided drug-substance expertise across mammalian cell culture, yeast and microbial expression systems, harvest, clarification, chromatography, filtration, UF/DF, and formulation. Supported drug-product operations including formulation, aseptic fill-finish, equipment qualification, media fills, container-closure integrity, visual inspection, cold chain, and PPQ readiness. Led technology transfer of a yeast-based recombinant-protein process and supported manufacturing-site readiness and validation. Supported design of a large-scale, predominantly single-use biologics facility using single-use bioreactors, disposable mixers, single-use flow paths, filtration systems, and chromatography skids. Evaluated facility fit, process flows, utilities, equipment selection, contamination control, capacity, capital requirements, operating costs, and supply risks. Worked with Manufacturing, Quality, Regulatory, Engineering, Validation, Procurement, Supply Chain, vendors, and contract manufacturers
Roche
Developed and scaled upstream and downstream processes for monoclonal antibodies, recombinant proteins, antibody-drug conjugates, and major biologics products including Avastin and Lucentis. Supported early-stage development, late-stage development, clinical manufacturing, pilot-plant operations, technology transfer, process characterization, validation readiness, and commercial manufacturing support. Developed mammalian cell-culture processes involving seed trains, media and feeds, bioreactors, oxygen transfer, gas control, mixing, scale-up, process intensification, and harvest optimization. Conducted media optimization, raw-material evaluation, nutrient and metabolite analysis, cell-growth improvement, productivity enhancement, and process-robustness studies. Developed downstream processes involving centrifugation, depth filtration, affinity chromatography, ion exchange, HIC, multimodal chromatography, viral inactivation, virus filtration, TFF, and UF/DF. Supported resin and membrane selection, impurity clearance, yield improvement, filter-sizing studies, hold-time studies, formulation, and bulk drug-substance handling. Led laboratory, pilot-scale, engineering, and scale-down studies to establish operating ranges and understand critical process parameters. Supported technology transfer, batch-record development, deviation investigations, manufacturing troubleshooting, CMC documentation, IND support, and process-development reports. Collaborated with Cell-Line Development, Analytical Development, Formulation, Drug Product, Manufacturing, Quality, Regulatory, Engineering, Automation, and Validation. Performed hands-on upstream and downstream process-development studies for mammalian-cell-based biologics. Operated shake flasks, bench bioreactors, pilot-scale equipment, filtration systems, chromatography skids, and TFF systems. Developed and optimized media, feeds, seed trains, cell-culture parameters, harvest conditions, clarification, purification, and formulation processes. Designed experiments, analyzed process data, prepared protocols and reports, and supported technical decisions for clinical and commercial programs. Supported pilot-plant campaigns, engineering runs, clinical manufacturing, equipment setup, process instructions, sampling plans, and deviation resolution. Transferred laboratory processes into pilot and manufacturing environments while supporting scalability, robustness, yield, and product quality.
Hourly rate
$1000